259 related articles for article (PubMed ID: 36310879)
21. Protection against Experimental Cryptococcosis following Vaccination with Glucan Particles Containing Cryptococcus Alkaline Extracts.
Specht CA; Lee CK; Huang H; Tipper DJ; Shen ZT; Lodge JK; Leszyk J; Ostroff GR; Levitz SM
mBio; 2015 Dec; 6(6):e01905-15. PubMed ID: 26695631
[TBL] [Abstract][Full Text] [Related]
22. Cryptococcus neoformans- and Cryptococcus gattii-specific IgG, IgA and IgM differ among children and adults with and without cryptococcosis from Colombia.
Becerra-Álvarez P; Escandón P; Lizarazo J; Quirós-Gómez Ó; Firacative C
Med Mycol; 2022 Sep; 60(9):. PubMed ID: 36066645
[TBL] [Abstract][Full Text] [Related]
23. Cryptococcus neoformans Chitin Synthase 3 Plays a Critical Role in Dampening Host Inflammatory Responses.
Hole CR; Lam WC; Upadhya R; Lodge JK
mBio; 2020 Feb; 11(1):. PubMed ID: 32071275
[No Abstract] [Full Text] [Related]
24. Clinical insights and epidemiology of central nervous system infection due to Cryptococcus neoformans/gattii species complexes: A prospective study from South India.
Lahiri S; Manjunath N; Bhat M; Hagen F; Bahubali VH; Palaniappan M; Maji S; Chandrashekar N
Med Mycol; 2020 Jul; 58(5):600-608. PubMed ID: 31578566
[TBL] [Abstract][Full Text] [Related]
25. Investigation of fluconazole heteroresistance in clinical and environmental isolates of Cryptococcus neoformans complex and Cryptococcus gattii complex in the state of Amazonas, Brazil.
Moreira IMB; Cortez ACA; de Souza ÉS; Pinheiro SB; de Souza Oliveira JG; Sadahiro A; Cruz KS; Matsuura ABJ; Melhem MSC; Frickmann H; de Souza JVB
Med Mycol; 2022 Mar; 60(3):. PubMed ID: 35084497
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Vitek MS for Differentiation of
Siqueira LPM; Gimenes VMF; de Freitas RS; Melhem MSC; Bonfietti LX; da Silva AR; Souza Santos LB; Motta AL; Rossi F; Benard G; de Almeida JN
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30429250
[No Abstract] [Full Text] [Related]
27. Cryptococcus and Phagocytes: Complex Interactions that Influence Disease Outcome.
Leopold Wager CM; Hole CR; Wozniak KL; Wormley FL
Front Microbiol; 2016; 7():105. PubMed ID: 26903984
[TBL] [Abstract][Full Text] [Related]
28. Comparison of
Oliveira LSS; Pinto LM; de Medeiros MAP; Toffaletti DL; Tenor JL; Barros TF; Neves RP; Neto RGL; Milan EP; Padovan ACB; Rocha WPDS; Perfect JR; Chaves GM
Front Cell Infect Microbiol; 2021; 11():642658. PubMed ID: 34277464
[TBL] [Abstract][Full Text] [Related]
29. An alternative method for the analysis of melanin production in Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato.
Brilhante RSN; España JDA; de Alencar LP; Pereira VS; Castelo-Branco DSCM; Pereira-Neto WA; Cordeiro RA; Sidrim JJC; Rocha MFG
Mycoses; 2017 Oct; 60(10):697-702. PubMed ID: 28699287
[TBL] [Abstract][Full Text] [Related]
30. [Mechanism of Cryptococcus Meningoencephalitis].
Miyazato A
Med Mycol J; 2016; 57(1):J27-32. PubMed ID: 26936349
[TBL] [Abstract][Full Text] [Related]
31. Melanin deposition in two
Chrissian C; Camacho E; Fu MS; Prados-Rosales R; Chatterjee S; Cordero RJB; Lodge JK; Casadevall A; Stark RE
J Biol Chem; 2020 Feb; 295(7):1815-1828. PubMed ID: 31896575
[No Abstract] [Full Text] [Related]
32. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
[TBL] [Abstract][Full Text] [Related]
33. Pyrifenox, an ergosterol inhibitor, differentially affects Cryptococcus neoformans and Cryptococcus gattii.
Silva VKA; May RC; Rodrigues ML
Med Mycol; 2020 Oct; 58(7):928-937. PubMed ID: 31915833
[TBL] [Abstract][Full Text] [Related]
34. Phagosomal F-Actin Retention by Cryptococcus gattii Induces Dendritic Cell Immunoparalysis.
Jamil K; Polyak MJ; Feehan DD; Surmanowicz P; Stack D; Li SS; Ogbomo H; Olszewski M; Ganguly A; Mody CH
mBio; 2020 Nov; 11(6):. PubMed ID: 33234684
[No Abstract] [Full Text] [Related]
35. What makes Cryptococcus gattii a pathogen?
Bielska E; May RC
FEMS Yeast Res; 2016 Feb; 16(1):fov106. PubMed ID: 26614308
[TBL] [Abstract][Full Text] [Related]
36. Cryptococcus and cryptococcosis in Cuba. A minireview.
Illnait-Zaragozi MT; Martínez-Machín GF; Fernández-Andreu CM; Perurena-Lancha MR; Hagen F; Meis JF
Mycoses; 2014 Dec; 57(12):707-17. PubMed ID: 25420448
[TBL] [Abstract][Full Text] [Related]
37. Differentiation of Cryptococcus neoformans varieties and Cryptococcus gattii using CAP59-based loop-mediated isothermal DNA amplification.
Lucas S; da Luz Martins M; Flores O; Meyer W; Spencer-Martins I; Inácio J
Clin Microbiol Infect; 2010 Jun; 16(6):711-4. PubMed ID: 19694768
[TBL] [Abstract][Full Text] [Related]
38. Promising whole-cell vaccines against cryptococcosis.
Ueno K; Tsuge S; Shimizu K; Miyazaki Y
Microbiol Immunol; 2023 May; 67(5):211-223. PubMed ID: 36786396
[TBL] [Abstract][Full Text] [Related]
39. Insights into the mechanisms of protective immunity against Cryptococcus neoformans infection using a mouse model of pulmonary cryptococcosis.
Wozniak KL; Ravi S; Macias S; Young ML; Olszewski MA; Steele C; Wormley FL
PLoS One; 2009 Sep; 4(9):e6854. PubMed ID: 19727388
[TBL] [Abstract][Full Text] [Related]
40. [CAP59 gene amplification in Cryptococcus neoformans and Cryptococcus gattii directly from a yeast suspension].
Siachoque N; Jewtuchowicz VM; Iovannitti C; Mujica MT
Rev Argent Microbiol; 2010; 42(2):91-4. PubMed ID: 20589327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
